secwatch.observer — SEC 8-K summary
======================================

Issuer:     TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
CIK:        0000818686
Form:       8-K
Filed at:   2023-10-04T23:59:59+00:00
Accession:  0001193125-23-250305
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Teva and Sanofi partner on anti-TL1A therapy TEV-574 for IBD; $500M upfront
---------------------------------------------------------------------------

- Teva receives €469M ($500M) upfront and up to €940M ($1B) in development/launch milestones.
- Companies share development costs equally and split net profits/losses in major markets.
- Sanofi leads Phase 3 program; Teva commercializes in Europe/Israel, Sanofi in North America/Asia.
- TEV-574 is in Phase 2b for ulcerative colitis and Crohn's disease; initial data expected in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/818686/000119312523250305/0001193125-23-250305-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/818686/000119312523250305/d547410d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-250305

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer